🏛️ Verified NIH Record • Updated 2026-08-10
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors (NCT07160725)
A Phase 1/2a, First-in-human, Open-label Study of BMS-986517 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors
🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Bristol-Myers Squibb
🩺 Plain-English Summary (8th-Grade Level)
A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors
Who can join: Review the eligibility criteria below.
Location: Local Institution - 0033 — Irvine, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- Local Institution - 0033 — Irvine, California
- USC/Norris Comprehensive Cancer Center — Los Angeles, California
- University of California, Irvine (UCI) Health - UC Irvine Medical Center — Orange, California
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
- Sanford Cancer Center — Sioux Falls, South Dakota
- START - Dallas Fort Worth — Fort Worth, Texas
- START San Antonio — San Antonio, Texas
- START Mountain Region — West Valley City, Utah
- Fred Hutchinson Cancer Center — Seattle, Washington
- Local Institution - 0034 — Guangzhou, Guangdong
- Herlev and Gentofte Hospital — Copenhagen, Capital Region
- Odense Universitetshospital — Odense, Region Syddanmark
- Copenhagen University Hospital Rigshospitalet — Copenhagen,
- National Cancer Center Hospital — Chuo-ku, Tokyo
- Local Institution - 0026 — Málaga, Andalusia
- Local Institution - 0022 — Badalona, Barcelona [Barcelona]
- Local Institution - 0024 — Barcelona, Barcelona [Barcelona]
- Clinica Universidad de Navarra — Pamplona, Navarre
- Hospital Universitario Fundación Jiménez Díaz — Madrid,
- Local Institution - 0023 — Madrid,
📞 Contact the Study Coordinator
Phone: (855) 907-3286
Email: Clinical.Trials@bms.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumours
- A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine — Beverly Hills, California
- Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours — New York, New York
- A Study of BI 3810944 in Patients With Advanced Cancer — Louisville, Kentucky
- A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors — Beverly Hills, California
- Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations — Anchorage, Alaska
Explore by condition: All Solid Tumours clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.